TY - JOUR
T1 - Overview of the cardiovascular effects of environmental metals
T2 - New preclinical and clinical insights
AU - Huang, Jiapeng
AU - El-Kersh, Karim
AU - Mann, Koren K.
AU - James, Katherine A.
AU - Cai, Lu
N1 - Funding Information:
The authors of this review were supported in part by the University of Louisville Executive Vice President for Research and Innovation Internal Grant (JH, LC); University of Louisville School of Medicine Basic Grant (JH, LC); National Institute of Environmental Health Sciences (P30ES030283 to JH, LC; 1R21ES021831 to KAJ); Gilead Sciences COMMIT COVID-19 RFP Program grant (Gilead IN-US-983-6063 to JH); National Center for Advancing Translational Sciences grant (1U18TR003787-01 to JH). Dr. El-Kersh has received institutional research grants from UT and J&J Actelion, has participated in advisory boards for UT and J&J Actelion, and has acted as a consultant for Acceleron and UT. Dr. Mann is supported by funding from the Canadian Institutes of Health Research (PJT-166142), the Heart and Stroke Foundation Canada (G-17-0018365), and the National Institute of Environmental Health Sciences (1 P42 ES033719-01).
Funding Information:
The authors of this review were supported in part by the University of Louisville Executive Vice President for Research and Innovation Internal Grant (JH, LC); University of Louisville School of Medicine Basic Grant (JH, LC); National Institute of Environmental Health Sciences ( P30ES030283 to JH, LC; 1R21ES021831 to KAJ); Gilead Sciences COMMIT COVID-19 RFP Program grant (Gilead IN-US-983-6063 to JH); National Center for Advancing Translational Sciences grant ( 1U18TR003787-01 to JH). Dr. El-Kersh has received institutional research grants from UT and J&J Actelion , has participated in advisory boards for UT and J&J Actelion, and has acted as a consultant for Acceleron and UT. Dr. Mann is supported by funding from the Canadian Institutes of Health Research ( PJT-166142 ), the Heart and Stroke Foundation Canada ( G-17-0018365 ), and the National Institute of Environmental Health Sciences ( 1 P42 ES033719-01 ).
Publisher Copyright:
© 2022
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Environmental causes of cardiovascular diseases (CVDs) are global health issues. In particular, an association between metal exposure and CVDs has become evident but causal evidence still lacks. Therefore, this symposium at the Society of Toxicology 2022 annual meeting addressed epidemiological, clinical, pre-clinical animal model-derived and mechanism-based evidence by five presentations: 1) An epidemiologic study on potential CVD risks of individuals exposed occupationally and environmentally to heavy metals; 2) Both presentations of the second and third were clinical studies focusing on the potential link between heavy metals and pulmonary arterial hypertension (PAH), by presenting altered blood metal concentrations of both non-essential and essential metals in the patients with PAH and potential therapeutic approaches; 3) Arsenic-induced atherosclerosis via inflammatory cells in mouse model; 4) Pathogenic effects on the heart by adult chronic exposure to very low-dose cadmium via epigenetic mechanisms and whole life exposure to low dose cadmium via exacerbating high-fat-diet-lipotoxicity. This symposium has brought epidemiologists, therapeutic industry, physicians, and translational scientists together to discuss the health risks of occupational and environmental exposure to heavy metals through direct cardiotoxicity and indirect disruption of homeostatic mechanisms regulating essential metals, as well as lipid levels. The data summarized by the presenters infers a potential causal link between multiple metals and CVDs and defines differences and commonalities. Therefore, summary of these presentations may accelerate the development of efficient preventive and therapeutic strategies by facilitating collaborations among multidisciplinary investigators.
AB - Environmental causes of cardiovascular diseases (CVDs) are global health issues. In particular, an association between metal exposure and CVDs has become evident but causal evidence still lacks. Therefore, this symposium at the Society of Toxicology 2022 annual meeting addressed epidemiological, clinical, pre-clinical animal model-derived and mechanism-based evidence by five presentations: 1) An epidemiologic study on potential CVD risks of individuals exposed occupationally and environmentally to heavy metals; 2) Both presentations of the second and third were clinical studies focusing on the potential link between heavy metals and pulmonary arterial hypertension (PAH), by presenting altered blood metal concentrations of both non-essential and essential metals in the patients with PAH and potential therapeutic approaches; 3) Arsenic-induced atherosclerosis via inflammatory cells in mouse model; 4) Pathogenic effects on the heart by adult chronic exposure to very low-dose cadmium via epigenetic mechanisms and whole life exposure to low dose cadmium via exacerbating high-fat-diet-lipotoxicity. This symposium has brought epidemiologists, therapeutic industry, physicians, and translational scientists together to discuss the health risks of occupational and environmental exposure to heavy metals through direct cardiotoxicity and indirect disruption of homeostatic mechanisms regulating essential metals, as well as lipid levels. The data summarized by the presenters infers a potential causal link between multiple metals and CVDs and defines differences and commonalities. Therefore, summary of these presentations may accelerate the development of efficient preventive and therapeutic strategies by facilitating collaborations among multidisciplinary investigators.
KW - Cardiovascular diseases
KW - Epidemiological evidence
KW - Metal toxicities
KW - Pulmonary hypertension, arsenics, cadmium
UR - http://www.scopus.com/inward/record.url?scp=85138538409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138538409&partnerID=8YFLogxK
U2 - 10.1016/j.taap.2022.116247
DO - 10.1016/j.taap.2022.116247
M3 - Article
C2 - 36122736
AN - SCOPUS:85138538409
VL - 454
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
SN - 0041-008X
M1 - 116247
ER -